The global gynecological cancer drugs market size was valued at $9,269 million in 2016, and is expected to reach $16,107 million by 2023, growing at a CAGR of 8.1% from 2017 to 2023. Research Beam Model: Research Beam Product ID: 2778358 5370 USD New
Gynecological Cancer Drugs Market by Therapeutic Modality (Chemotherapy, Targeted Therapy, and Hormonal Therapy) and Indication (Cervical Cancer, Uterine Cancer, Ovarian Cancer, and Vaginal & Vulvar Cancer) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

Gynecological Cancer Drugs Market by Therapeutic Modality (Chemotherapy, Targeted Therapy, and Hormonal Therapy) and Indication (Cervical Cancer, Uterine Cancer, Ovarian Cancer, and Vaginal & Vulvar Cancer) - Global Opportunity Analysis and Industry Forecast, 2017-2023

 
  • Category : Healthcare
  • Published On : December  2017
  • Pages : 188
 
 

The global gynecological cancer drugs market size was valued at $9,269 million in 2016, and is expected to reach $16,107 million by 2023, growing at a CAGR of 8.1% from 2017 to 2023.

Cancer refers to a specific group of disorder, which leads to abnormal cell growth within any part of the body. Gynecological cancer refers to a group of cancers that affect the reproductive organs of a female, such as uterus, endometrium, ovary, peritoneum, fallopian tubes, vagina, vulva, cervix, and muscle & tissue supporting the uterus.

High incidence of gynecological cancers, rise in importance of targeted drug therapies, rise in investment from government, public & private organizations for the development of novel drugs to treat cancer, and increase in risk factors that lead to cancer drive the market growth. However, high cost of drug development and threat of failure & adverse effects of cancer drug therapy restrain the growth of this market. Conversely, advancement of cancer drug research and advent of personalized medicine approach are expected to provide numerous opportunities for market growth during the forecast period.

The report segments the market based on therapeutic modality, indication, and region. Based on therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. Geographically, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2016 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Analysis by therapeutic modality helps to understand the various types of treatment modalities for treatment of gynecological cancer patients.
  • Comprehensive analysis of all geographical regions is provided, which helps to determine the prevailing opportunities.
  • Key players are profiled and their strategies are analyzed thoroughly, which helps to understand competitive outlook of the global market.

KEY MARKET SEGMENTS

By Therapeutic Modality

  • Chemotherapy
  • Targeted Therapy
  • Hormonal Therapy

By Indication

  • Uterine Cancer
  • Ovarian Cancer
  • Vaginal & Vulvar Cancer
  • Cervical Cancer

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • Apotex Inc.
  • AstraZeneca Plc  
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2015-2017

3.2.2.1. Top Winning Strategies, By Year, 2014-2017*
3.2.2.2. Top Winning Strategies, By Development, 2014-2017* (%)
3.2.2.3. Top Winning Strategies, By Company, 2014-2017*

3.3. TOP PLAYER POSITIONING, 2016
3.4. MARKET DYNAMICS

3.4.1. Drivers

3.4.1.1. Surge in incidence of gynecological cancers
3.4.1.2. Growing importance of targeted drug therapies
3.4.1.3. Increase in investment from government, public, and private sector

3.4.2. Restraints

3.4.2.1. High cost of drug development and threat of failure
3.4.2.2. Adverse effects of cancer drug therapy

3.4.3. Opportunities

3.4.3.1. Advancement of cancer drugs research
3.4.3.2. Personalized medicine approach

3.5. CLINICAL TRIALS

CHAPTER 4 GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. CHEMOTHERAPY

4.2.1. Key market trends growth factors and opportunities
4.2.2. Market size and forecast

4.3. TARGETED THERAPY

4.3.1. Key market trends growth factors and opportunities
4.3.2. Market size and forecast

4.4. HORMONAL THERAPY

4.4.1. Key market trends growth factors and opportunities
4.4.2. Market size and forecast

CHAPTER 5 GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. UTERINE CANCER

5.2.1. Market size and forecast

5.3. OVARIAN CANCER

5.3.1. Market size and forecast

5.4. VAGINAL & VULVAR CANCER

5.4.1. Market size and forecast

5.5. CERVICAL CANCER

5.5.1. Market size and forecast

CHAPTER 6 GYNECOLOGICAL CANCER DRUGS MARKET, BY REGION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends growth factors & opportunities
6.2.2. Market size & forecast

6.2.2.1. U.S.

6.2.2.1.1. U.S. gynecological cancer drugs market by therapeutic modality
6.2.2.1.2. U.S. gynecological cancer drugs market by indication

6.2.2.2. Canada

6.2.2.2.1. Canada gynecological cancer drugs market by therapeutic modality
6.2.2.2.2. Canada gynecological cancer drugs market by indication

6.2.2.3. Mexico

6.2.2.3.1. Mexico gynecological cancer drugs market by therapeutic modality
6.2.2.3.2. Mexico gynecological cancer drugs market by indication

6.2.3. North America gynecological cancer drugs market by therapeutic modality
6.2.4. North America gynecological cancer drugs market by indication

6.3. EUROPE

6.3.1. Key market trends growth factors & opportunities
6.3.2. Market size & forecast

6.3.2.1. Germany

6.3.2.1.1. Germany gynecological cancer drugs market by therapeutic modality
6.3.2.1.2. Germany gynecological cancer drugs market by indication

6.3.2.2. France

6.3.2.2.1. France gynecological cancer drugs market by therapeutic modality
6.3.2.2.2. France gynecological cancer drugs market by indication

6.3.2.3. UK

6.3.2.3.1. UK gynecological cancer drugs market by therapeutic modality
6.3.2.3.2. UK gynecological cancer drugs market by indication

6.3.2.4. Italy

6.3.2.4.1. Italy gynecological cancer drugs market by therapeutic modality
6.3.2.4.2. Italy gynecological cancer drugs market by indication

6.3.2.5. Spain

6.3.2.5.1. Spain gynecological cancer drugs market by therapeutic modality
6.3.2.5.2. Spain gynecological cancer drugs market by indication

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe gynecological cancer drugs market by therapeutic modality
6.3.2.6.2. Rest of Europe gynecological cancer drugs market by indication

6.3.3. Europe gynecological cancer drugs market by therapeutic modality
6.3.4. Europe gynecological cancer drugs market by indication

6.4. ASIA-PACIFIC

6.4.1. Key market trends growth factors & opportunities
6.4.2. Market size & forecast

6.4.2.1. Japan

6.4.2.1.1. Japan gynecological cancer drugs market by therapeutic modality
6.4.2.1.2. Japan gynecological cancer drugs market by indication

6.4.2.2. China

6.4.2.2.1. China gynecological cancer drugs market by therapeutic modality
6.4.2.2.2. China gynecological cancer drugs market by indication

6.4.2.3. India

6.4.2.3.1. INDIA gynecological cancer drugs market by therapeutic modality
6.4.2.3.2. INDIA gynecological cancer drugs market by indication

6.4.2.4. Australia

6.4.2.4.1. Australia gynecological cancer drugs market by therapeutic modality
6.4.2.4.2. Australia gynecological cancer drugs market by indication

6.4.2.5. South Korea

6.4.2.5.1. South Korea gynecological cancer drugs market by therapeutic modality
6.4.2.5.2. South Korea gynecological cancer drugs market by indication

6.4.2.6. Rest of Asia-Pacific

6.4.2.6.1. Rest of Asia-Pacific gynecological cancer drugs market by therapeutic modality
6.4.2.6.2. Rest of Asia-Pacific gynecological cancer drugs market by indication

6.4.3. Asia-Pacific gynecological cancer drugs market by therapeutic modality
6.4.4. Asia-Pacific gynecological cancer drugs market by indication

6.5. LAMEA

6.5.1. Key market trends growth factors & opportunities
6.5.2. Market size & forecast

6.5.2.1. Brazil

6.5.2.1.1. Brazil gynecological cancer drugs market by therapeutic modality
6.5.2.1.2. Brazil gynecological cancer drugs market by indication

6.5.2.2. South Africa

6.5.2.2.1. South Africa gynecological cancer drugs market by therapeutic modality
6.5.2.2.2. South Africa gynecological cancer drugs market by indication

6.5.2.3. Saudi Arabia

6.5.2.3.1. Saudi Arabia gynecological cancer drugs market by therapeutic modality
6.5.2.3.2. Saudi Arabia gynecological cancer drugs market by indication

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Rest of LAMEA gynecological cancer drugs market by therapeutic modality
6.5.2.4.2. Rest of LAMEA gynecological cancer drugs market by indication

6.5.3. LAMEA gynecological cancer drugs market by therapeutic modality
6.5.4. LAMEA gynecological cancer drugs market by indication

CHAPTER 7 COMPANY PROFILES

7.1. APOTEX INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio

7.2. ASTRAZENECA PLC

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. BRISTOL-MYERS SQUIBB COMPANY

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. ELI LILLY AND COMPANY

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance

7.5. F. HOFFMANN-LA ROCHE LTD

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. GLAXOSMITHKLINE PLC

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. MERCK & CO., INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. NOVARTIS AG

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. PFIZER INC

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. TEVA PHARMACEUTICAL INDUSTRIES LTD

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance

LIST OF TABLES

TABLE 1. TOP 20 COUNTRIES WITH HIGHEST INCIDENCE OF OVARIAN CANCER, 2012
TABLE 2. TOP 20 COUNTRIES WITH HIGHEST INCIDENCE OF CERVICAL CANCER, 2012
TABLE 3. TOP 20 COUNTRIES WITH HIGHEST INCIDENCE OF ENDOMETRIAL CANCER, 2012
TABLE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016 - 2023 ($MILLION)
TABLE 5. CHEMOTHERAPY DRUGS MARKET, BY REGION, 2016 - 2023 ($MILLION)
TABLE 6. TARGETED THERAPY DRUGS MARKET, BY REGION, 2016 - 2023 ($MILLION)
TABLE 7. HORMONAL THERAPY DRUGS MARKET, BY REGION, 2016 - 2023 ($MILLION)
TABLE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 9. UTERINE CANCER DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 10. DRUGS APPROVED FOR OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
TABLE 11. DRUG COMBINATIONS USED IN OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
TABLE 12. OVARIAN CANCER DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 13. INCIDENCE AND MORTALITY OF VAGINAL & VULVAR CANCERS IN U.S. (2014)
TABLE 14. DRUGS FOR TREATMENT OF VAGINAL & VULVAR CANCERS
TABLE 15. VAGINAL & VULVAR CANCER DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 16. DRUGS FOR TREATMENT OF CERVICAL CANCER
TABLE 17. CERVICAL CANCER DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 18. GYNECOLOGICAL CANCER DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 19. INCIDENCE RATES OF GYNECOLOGICAL CANCERS IN U.S., BY STATE, 2014
TABLE 20. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 21. U.S. GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 22. U.S. GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 23. CANADA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 24. CANADA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 25. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 26. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 27. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 28. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 29. ESTIMATED INCIDENCE AND MORTALITY OF GYNECOLOGICAL CANCERS IN EUROPE, BY COUNTRY, 2012
TABLE 30. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 31. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 32. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 33. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 34. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 35. UK GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 36. UK GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 37. ITALY GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 38. ITALY GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 39. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 40. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 41. REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 42. REST OF EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 43. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 44. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 45. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 46. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 47. JAPAN GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 48. CHINA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 49. CHINA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 50. INDIA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 51. INDIA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 52. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 53. AUSTRALIA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 54. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 55. SOUTH KOREA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 56. REST OF ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 57. REST OF ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 58. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 59. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 60. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 61. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 62. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 63. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 64. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 65. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 66. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 67. REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 68. REST OF LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 69. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY THERAPEUTIC MODALITY, 2016-2023 ($MILLION)
TABLE 70. LAMEA GYNECOLOGICAL CANCER DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 71. APOTEX: COMPANY SNAPSHOT
TABLE 72. APOTEX: PRODUCT PORTFOLIO
TABLE 73. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 74. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 75. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 76. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 77. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 78. LILLY: COMPANY SNAPSHOT
TABLE 79. LILLY: OPERATING SEGMENTS
TABLE 80. LILLY: PRODUCT PORTFOLIO
TABLE 81. ROCHE: COMPANY SNAPSHOT
TABLE 82. ROCHE: OPERATING SEGMENTS
TABLE 83. ROCHE: PRODUCT PORTFOLIO
TABLE 84. GSK: COMPANY SNAPSHOT
TABLE 85. GSK: OPERATING SEGMENTS
TABLE 86. GSK: PRODUCT PORTFOLIO
TABLE 87. MERCK: COMPANY SNAPSHOT
TABLE 88. MERCK: OPERATING SEGMENTS
TABLE 89. MERCK: PRODUCT PORTFOLIO
TABLE 90. NOVARTIS: COMPANY SNAPSHOT
TABLE 91. NOVARTIS: OPERATING SEGMENTS
TABLE 92. NOVARTIS: PRODUCT PORTFOLIO
TABLE 93. PFIZER: COMPANY SNAPSHOT
TABLE 94. PFIZER: OPERATING SEGMENTS
TABLE 95. PFIZER: PRODUCT PORTFOLIO
TABLE 96. TEVA: COMPANY SNAPSHOT
TABLE 97. TEVA: OPERATING SEGMENTS
TABLE 98. TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. GYNECOLOGICAL CANCER DRUGS MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. TOP PLAYER POSITIONING, 2016
FIGURE 4. CLINICAL TRIALS FOR GYNECOLOGICAL CANCER DRUGS, BY CANCER TYPE (%)
FIGURE 5. CLINICAL TRIALS FOR GYNECOLOGICAL CANCER DRUGS, BY REGION (%)
FIGURE 6. CLINICAL TRIALS FOR OVARIAN CANCER DRUGS, BY REGION (%)
FIGURE 7. CLINICAL TRIALS FOR CERVICAL CANCER DRUGS, BY REGION (%)
FIGURE 8. CLINICAL TRIALS FOR UTERINE CANCER DRUGS, BY REGION (%)
FIGURE 9. CLINICAL TRIALS FOR VAGINAL CANCER DRUGS, BY REGION (%)
FIGURE 10. CLINICAL TRIALS FOR VULVAR CANCER DRUGS, BY REGION (%)
FIGURE 11. INCIDENCE OF CERVICAL CANCER IN ASIA, 2012
FIGURE 12. COMPARISON OF THE TEN MOST FREQUENT CANCERS IN WOMEN AGED 15-44 YEARS IN ASIA, 2012
FIGURE 13. INCIDENCE OF CERVICAL CANCER IN LAMEA, 2012
FIGURE 14. ASTRAZENECA: NET SALES, 2014-2016 ($MILLION)
FIGURE 15. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 16. BRISTOL-MYERS SQUIBB: NET SALES, 2014-2016 ($MILLION)
FIGURE 17. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 18. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 19. LILLY: NET SALES, 2014-2016 ($MILLION)
FIGURE 20. LILLY: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 21. LILLY: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 22. ROCHE: NET SALES, 2014-2016 ($MILLION)
FIGURE 23. ROCHE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 24. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 25. GSK: NET SALES, 2014-2016 ($MILLION)
FIGURE 26. GSK: REVENUE SHARE BY PRODUCT, 2016 (%)
FIGURE 27. GSK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 28. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 29. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 30. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 31. NOVARTIS: NET SALES, 2014-2016 ($MILLION)
FIGURE 32. NOVARTIS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 33. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 34. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 35. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 36. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 37. TEVA: NET SALES, 2014-2016 ($MILLION)
FIGURE 38. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 39. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)